Altimmune/$ALT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Altimmune
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Ticker
$ALT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
59
ISIN
US02155H2004
Website
Altimmune Metrics
BasicAdvanced
$443M
-
-$1.25
1.11
-
Price and volume
Market cap
$443M
Beta
1.11
52-week high
$9.46
52-week low
$3.55
Average daily volume
2.3M
Financial strength
Current ratio
15.846
Quick ratio
15.543
Long term debt to equity
0.944
Total debt to equity
1.116
Interest coverage (TTM)
-10,910.33%
Management effectiveness
Return on assets (TTM)
-35.51%
Return on equity (TTM)
-57.28%
Valuation
Price to revenue (TTM)
19,711.191
Price to book
2.99
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
-4.907
Growth
Revenue change (TTM)
-95.12%
Earnings per share change (TTM)
-21.28%
3-year revenue growth (CAGR)
-82.30%
3-year earnings per share growth (CAGR)
-19.42%
What the Analysts think about Altimmune
Analyst ratings (Buy, Hold, Sell) for Altimmune stock.
Altimmune Financial Performance
Revenues and expenses
Altimmune Earnings Performance
Company profitability
Altimmune News
AllArticlesVideos
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GlobeNewsWire·3 weeks ago
Altimmune to Participate at Two Upcoming Investor Conferences
GlobeNewsWire·3 weeks ago
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Altimmune stock?
Altimmune (ALT) has a market cap of $443M as of June 06, 2025.
What is the P/E ratio for Altimmune stock?
The price to earnings (P/E) ratio for Altimmune (ALT) stock is 0 as of June 06, 2025.
Does Altimmune stock pay dividends?
No, Altimmune (ALT) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Altimmune dividend payment date?
Altimmune (ALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Altimmune?
Altimmune (ALT) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.